Q1 Earnings Estimate for Stryker Issued By Roth Capital

Stryker Co. (NYSE:SYK) – Roth Capital issued their Q1 2025 earnings estimates for shares of Stryker in a report released on Wednesday, January 29th. Roth Capital analyst J. Wittes expects that the medical technology company will post earnings of $2.98 per share for the quarter. The consensus estimate for Stryker’s current full-year earnings is $12.06 per share. Roth Capital also issued estimates for Stryker’s Q2 2025 earnings at $3.13 EPS, Q3 2025 earnings at $3.32 EPS, Q4 2025 earnings at $4.07 EPS, FY2025 earnings at $13.50 EPS and FY2026 earnings at $14.95 EPS.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter in the previous year, the firm earned $3.46 earnings per share.

Several other research firms also recently commented on SYK. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday. Evercore ISI increased their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $413.45.

Stryker Stock Performance

Shares of NYSE SYK opened at $390.98 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market cap of $149.05 billion, a price-to-earnings ratio of 41.91, a P/E/G ratio of 2.68 and a beta of 0.95. The stock’s fifty day moving average price is $376.44 and its two-hundred day moving average price is $361.98. Stryker has a one year low of $314.05 and a one year high of $406.19.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently added to or reduced their stakes in SYK. Parnassus Investments LLC bought a new stake in shares of Stryker in the third quarter worth $762,798,000. International Assets Investment Management LLC boosted its holdings in Stryker by 66,967.5% in the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock valued at $308,433,000 after acquiring an additional 852,496 shares during the last quarter. RTW Investments LP acquired a new stake in Stryker during the 3rd quarter valued at approximately $143,392,000. State Street Corp lifted its position in shares of Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the period. Finally, FMR LLC boosted its stake in shares of Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after purchasing an additional 215,782 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.